AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ragweed Pollen Allergy Pipeline Review, H1 2019 Featuring ALK-Abello, Allergy Therapeutics, Anergis, Astellas Pharma, & Biomay - ResearchAndMarkets.com

April 5, 2019

DUBLIN--(BUSINESS WIRE)--Apr 5, 2019--The “Ragweed Pollen Allergy - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Ragweed Pollen Allergy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ragweed Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ragweed Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Ragweed Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Unknown stages are 1, 1, 3 and 1 respectively.

Ragweed Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ragweed Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Ragweed Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ragweed Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ragweed Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ragweed Pollen Allergy (Immunology)

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Ragweed Pollen Allergy - Overview
  4. Ragweed Pollen Allergy - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Ragweed Pollen Allergy - Therapeutics Assessment
  9. Assessment by Route of Administration
  10. Assessment by Molecule Type

Ragweed Pollen Allergy - Companies Involved in Therapeutics Development

  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Astellas Pharma Inc
  • Biomay AG

Ragweed Pollen Allergy - Drug Profiles

  • Allergan for Rag Weed Pollen Allergy - Drug Profile
  • BM-34 - Drug Profile
  • LAMP-Vax - Drug Profile
  • PL-101 - Drug Profile
  • Pollinex Ragweed - Drug Profile
  • Short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9b82ji

View source version on businesswire.com:https://www.businesswire.com/news/home/20190405005194/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/05/2019 08:21 AM/DISC: 04/05/2019 08:21 AM

http://www.businesswire.com/news/home/20190405005194/en